Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.31 |
| ▸ | F11 | P03951 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5109499 | 1.00 | NPC1 (0.33) | NPC1AGTR1F11 | |
| SCHEMBL4962499 | 0.91 | NPC1 (0.33) | NPC1 | |
| SCHEMBL5118501 | 0.91 | NPC1 (0.33) | NPC1 | |
| SCHEMBL4664726 | 0.88 | KDM4E (0.34) | — | |
| SCHEMBL4664638 | 0.85 | F11 (0.37) | NPC1F11 | |
| SCHEMBL4664634 | 0.85 | NPC1 (0.36) | NPC1 | |
| SCHEMBL4963099 | 0.83 | NPC1 (0.34) | NPC1 | |
| SCHEMBL5138943 | 0.82 | CXCR2 (0.33) | — | |
| SCHEMBL4662901 | 0.82 | CXCR2 (0.33) | — | |
| SCHEMBL4664643 | 0.82 | CXCR2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280855-A1 | Process For the Production of Intermediates For the Preparation of Tricyclic Benzimidazoles | NYCOMED GMBH (DE) | 2008-11-13 | — | — | US | disclosed |
| EP-1863820-A1 | THIOAMIDE-SUBSTITUTED TRICYCLIC BENZIMIDAZOLES USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISEASES | Nycomed GmbH (DE) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006100255-A1 | THIOAMIDE-SUBSTITUTED TRICYCLIC BENZIMIDAZOLES USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISEASES | NYCOMED GMBH (DE) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280855-A1 | Process For the Production of Intermediates For the Preparation of Tricyclic Benzimidazoles | CYP1B1, CYP1A1, CYP3A4 | NPC1 1421/4885AGTR1 820/4885F11 415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.